[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"tumor-microenvironment\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:tumor-microenvironment":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,45,74,103,133,165],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100587550","organoid-models-of-hepatocellular-carcinoma-100587550",false,"NCT06929845","Organoid Models of Hepatocellular Carcinoma","Organoid Models of Hepatocellular Carcinoma to Test Treatment Efficacy, Exploring Correlations With Tumor Microenvironment and Gut-liver-tumor Axis.","Inclusion Criteria:\n\n* Capacity to express informed consent;\n* Age ≥18 years;\n* Suspected radiological diagnosis of HCC or diagnosis of HCC with indications for surgical resection.\n\nExclusion Criteria:\n\n* Age \\\u003C 18 years;\n* Contraindications to liver biopsy (ascites, platelets\\\u003C50,000, INR\\>1.7);\n* Contraindications to HCC resection surgery;\n* Active viral infection;\n* Refusal to sign informed consent to participate in the study.","ALL","18 Years",{"count":19,"type":20},150,"ESTIMATED","INTERVENTIONAL",[23],"NA","A promising tool to elucidate the molecular characteristics of HCC are patient-derived organoids (PDOs), three-dimensional cultures of cells that self-organise according to tissue-specific patterns and can be used to test the susceptibility of a specific tumour to anticancer agents. In this study, PDOs for HCC will be developed that closely resemble the tumour microenvironment in vivo and mimic the crosstalk of the gut-liver axis to establish a correlation with patient prognosis and test the efficacy of available systemic therapies.",[26,27,28,29,30,31],"Hepatocellular Carcinoma","Organoids","Gut Microbiota","Tumor Microenvironment","System Disorders, Digestive","Surgery","RECRUITING","2026-05-18",{"date":35,"type":36},"2026-05-19","ACTUAL",{"date":38,"type":36},"2024-10-01",{"date":40,"type":20},"2026-12-31",{"name":42,"class":43},"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","OTHER",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":53,"targetDuration":4,"studyType":21,"phases":55,"briefSummary":56,"conditions":57,"keywords":61,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":44},"100621807","will-a-pre-therapy-exercise-intervention-improve-the-outcomes-of-patients-with-advanced-oesophageal-cancer-100621807","NCT07375420","Will a Pre-therapy Exercise Intervention Improve the Outcomes of Patients With Advanced Oesophageal Cancer?","Optimising Prehabilitation Exercise to Enhance Tumour Outcomes in Advanced Oesophageal Cancer","OPTIMUS","Inclusion Criteria:\n\n* Adults with resectable oesophageal adenocarcinoma who are planned for neoadjuvant chemotherapy followed by surgery\n\nExclusion Criteria:\n\n* Inability to carry out CPET or exercise due to underlying health conditions\n* pregnancy\n* \\\u003C18 years old",{"count":54,"type":20},50,[23],"Background\n\nRegular exercise can significantly improve physical and mental health during cancer treatment and reduce the time needed in the hospital. Animal studies suggest that exercise training can also reduce the number of cancer cells. For example, exercise training in mice produces more immune cells in the tumour. These immune cells in the tumour contribute to the destruction and reduction of the size of the tumour and are a vital component of effective immunotherapy (cancer treatment that helps the immune system fight cancer).\n\nIn humans, exercise training and the immune response in tumours are less understood. Only 1 study has investigated the effect of a single exercise session before surgical removal of the prostate in prostate cancer patients. As the benefits of exercise are gained from weeks\u002Fmonths of exercise, no effect on the immune cells in the tumours were found.\n\nThe investigators have carried out a previous study looking at how exercise affects fitness before major surgery. After this they used state-of-the-art methods to detect and visualise immune cells within the tumour. Compared with the patients who did not exercise, the exercise group had significantly more immune cells in their tumours, consisting of a group of cells that are important for killing cancerous cells called CD8+ T cells. CD8+ T cells in tumours are associated with improved survival outcomes.\n\nImportantly, they found a link between changes in fitness and the amount of these cells in the tumour. This suggests that if there is increase in fitness, there also an increase in the frequency of these cells in the tumour. Therefore, the investigators propose performing a clinical trial to find out the best level of exercise patients need to sustain before surgery to produce this improved immune response.\n\nThe trial will aim to understand how this happens and how the entry of immune cells into the tumour changes the environment around a tumour. The investigators consist of a team of exercise immunologists, tumour immunologists and clinicians working with the Human Performance Institute at the University of Surrey in collaboration with the Royal Surrey NHS Trust.\n\nHow it will be done\n\nThe investigators will assess immune cell response in blood samples obtained from oesophageal cancer patients before, during and after a high or low intensity exercise programme. Following the exercise programme, tumour tissue removed at surgery from these patients will be used to investigate the the presence and quantity of these immune cells.\n\nPotential impact\n\nA better understanding of this is important, as current anti-cancer immune-based therapeutics work best when there is a an immune response within the patient's tumour. Generating evidence that exercise can improve the immune response against the tumour in patients with oesophageal cancer would provide significant justification for introducing \"personalised\" exercise programmes to improve treatment outcomes.",[58,59,29,60],"Oesophageal Adenocarcinoma","T Cells","Exercise",[62,63,64],"oesophageal cancer","exercise","tumour microenvironment","2026-01-29",{"date":67,"type":36},"2026-02-02",{"date":69,"type":36},"2024-04-26",{"date":71,"type":20},"2028-10-30",{"name":73,"class":43},"University of Surrey",{"id":75,"slug":76,"hasResults":11,"nctId":77,"briefTitle":78,"officialTitle":78,"acronym":79,"eligibilityCriteria":80,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":81,"targetDuration":4,"studyType":21,"phases":83,"briefSummary":84,"conditions":85,"keywords":89,"overallStatus":93,"whyStopped":4,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":44},"100609229","correlative-analysis-between-magnetic-resonance-spectroscopy-mrs-and-essential-clinicobiological-data-in-glioblatoma-multiforme-gbm-100609229","NCT07211841","Correlative Analysis Between Magnetic Resonance Spectroscopy (MRS) and Essential Clinicobiological Data in Glioblatoma Multiforme (GBM)","GLIOMIT","Inclusion Criteria:\n\n* Patients consecutively identified in the multidisciplinary consultation meeting of neurooncology with a new diagnosis of GBM \u002F a probable diagnosis of GBM. - Patients that have not started radiochemotherapy ;\n* Adult \\> 18 yrs\n* socially-insured,\n* having given consent.\n\nExclusion Criteria:\n\n* minor patients,\n* pregnant\u002Flactating women,\n* patients under guardianship,\n* curatorship,\n* protection of justice or deprived of liberty",{"count":82,"type":20},30,[23],"Glioblastoma multiforme (GBM) is the most common primary brain tumor, and it is well-known to be associated with a poor prognosis. MRI is the key medical technique for the diagnosis and the follow-up of GBM. By allowing for MRS studies, MRI permits a non-invasive characterization of the TME of GBM, including their metabolic characterization. The investigators propose to address the link between the MRS profile of GBM and basic clinical and biological parameters, with the aim of : i) identifying correlations between these parameters, ii) attempting to integrate clinical, biological and spectroscopic profiles of GBM. The investigators plan to recruit 30 newly diagnosed GBM patients for which surgery \u002F radiochemotherapy will be proposed in the Medical oncology unit of Amiens University Hospital. Following inclusion of patients with probable GBM, MRS study will be performed during the first (pre-therapeutic) MRI examination. Basic clinical and biological parameters of the blood (CRP, complete blood count, fibrinogen, lactate and choline) will be assessed. A metabolomic study will also be performed on the plasma of GBM patients before any therapeutics. A second biological, post-therapeutic assesment (one month after surgery\u002Fradiochemotherapy) will allow the same analyses (basic biological parameters + plasma metabolomics), in order to examine the stability of the blood parameters.",[86,87,29,88],"Glioblastoma","MRI Spectroscopy","Biomarkers \u002F Blood",[86,90,91,92],"MRI spectroscopy","Tumor microenvironment","biomarkers","NOT_YET_RECRUITING","2025-11-17",{"date":96,"type":36},"2025-11-19",{"date":98,"type":20},"2025-12",{"date":100,"type":20},"2029-04",{"name":102,"class":43},"Centre Hospitalier Universitaire, Amiens",{"id":104,"slug":105,"hasResults":11,"nctId":106,"briefTitle":107,"officialTitle":108,"acronym":109,"eligibilityCriteria":110,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":111,"targetDuration":4,"studyType":21,"phases":113,"briefSummary":115,"conditions":116,"keywords":117,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":123,"lastUpdatePostDateStruct":124,"startDateStruct":126,"completionDateStruct":128,"leadSponsor":130,"locationsCount":132},"100568948","phase-2-metformin-as-a-metabolic-intervention-in-oesophageal-adenocarcinomas-to-improve-response-to-neoadjuvant-chemoradiotherapy-100568948","NCT06687876","Metformin as a Metabolic Intervention in Oesophageal Adenocarcinomas to Improve Response to Neoadjuvant Chemoradiotherapy","Metformin as a Metabolic Intervention in Oesophageal Adenocarcinomas to Improve Response to Neoadjuvant Chemoradiotherapy.","MEMENTO","Inclusion Criteria:\n\n* Surgical resectable (\\\u003CT4b, N0 or N+, M0), and histologically proven adenocarcinoma of the oesophagus or gastro-oesophageal junction planning to undergo neoadjuvant chemoradiotherapy.\n* Adult patients (age ≥ 18 years).\n* ECOG performance status 0 or 1 (cf. Appendix A).\n* Adequate hematological, renal and hepatic functions defined as:\n\n  * Absolute Neutrophil Count ≥ 1.5 x 10\\^9\u002FL\n  * Platelets ≥ 100 x 10\\^9\u002FL\n  * Hemoglobin ≥ 5.6 mmol\n  * Total bilirubin ≤ 1.5 x upper normal limit\n  * Creatinine clearance (Cockroft) \\> 30 ml\u002Fmin\n* Patients must be willing to undergo two endoscopies for investigational purposes.\n* Written, voluntary informed consent.\n* Patients must be accessible to follow up and management in the treatment center.\n\nExclusion Criteria:\n\n* Patients diagnosed with diabetes mellitus type 1 or 2 receiving anti-diabetic drugs.\n* Patients prescribed metformin or another anti-diabetic drug for any reason.\n* Patients allergic or intolerant to metformin.\n* Excessive alcohol consumption.\n* Use of OCT1\u002FOCT2 inhibitors (e.g. verapamil, cimetidine, dolutegravir, isavuonazol, trimethoprim, vandetanib, crizotinib and Olaparib).\n* Use of OCT1\u002FOCT2 inducers (e.g. rifampicine).\n* Use of immunosuppressive medication (corticosteroids, cyclosporine, tacrolimus, sirolimus, everolimus, cyclophosphamide).\n* Previous systemic therapy or radiotherapy on the oesophagus.\n* Severe renal impairment (CLcr ≤ 30 ml\u002Fmin).\n* Past (within 5 years) or current history of malignancy other than entry diagnosis interfering with prognosis of oesophageal cancer.\n* Previous systemic therapy for other forms of cancer within the last six months.\n* Patients with prior allogeneic stem cell or solid organ transplantation\n* Pregnancy (positive serum pregnancy test), planning to become pregnant, and lactation.\n* Clinically significant cardiovascular disease (including myocardial infarction, unstable angina, symptomatic congestive heart failure, serious uncontrolled cardiac arrhythmia) precluding major surgery.\n* Pulmonary fibrosis, active, non-infectious pneumonitis and\u002For severely impaired lung function precluding major surgery and\u002For radiation.\n* Serious underlying medical condition which would impair the ability of the patient to receive the planned treatment, including prior allergic reactions to drugs containing Cremophor, such as teniposide or cyclosporine.\n* Dementia or altered mental status that would prohibit the understanding and giving of informed consent.",{"count":112,"type":20},14,[114],"PHASE2","The primary objective of this study is to investigate whether two weeks of metformin treatment can activate the tumour microenvironment in patients with stage II and III oesophageal adenocarcinomas.",[58,29],[118,119,62,120,121,122],"metabolic intervention","adenocarcinoma","metformin","tumor microenvironment","neoadjuvant chemoradiotherapy","2025-07-09",{"date":125,"type":36},"2025-07-10",{"date":127,"type":36},"2025-03-09",{"date":129,"type":20},"2030-12",{"name":131,"class":43},"Amsterdam UMC, location VUmc",2,{"id":134,"slug":135,"hasResults":11,"nctId":136,"briefTitle":137,"officialTitle":137,"acronym":138,"eligibilityCriteria":139,"healthyVolunteers":11,"sex":16,"minAge":140,"maxAge":141,"enrollmentInfo":142,"targetDuration":144,"studyType":145,"phases":4,"briefSummary":146,"conditions":147,"keywords":151,"overallStatus":93,"whyStopped":4,"lastUpdateSubmitDate":156,"lastUpdatePostDateStruct":157,"startDateStruct":159,"completionDateStruct":161,"leadSponsor":163,"locationsCount":4},"100575739","precision-therapy-based-on-immune-microenvironment-by-transcriptome-sequencing-of-osteosarcoma-a-prospective-multi-cohort-exploratory-clinical-study-100575739","NCT06776198","Precision Therapy Based on Immune Microenvironment by Transcriptome Sequencing of Osteosarcoma, a Prospective, Multi-cohort Exploratory Clinical Study","PTMTO","Inclusion Criteria:\n\n* (i) patients who have been suspected for osteosarcoma with enough clinical or radiographic information;\n* (ii) patients who have evaluable lesions to resect or follow;\n* (iii) patients who are planned to be operate with enough flesh specimens for this study.\n\nExclusion Criteria:\n\n* (i) clinical information was not complete;\n* (ii) lost to follow-up.","8 Years","70 Years",{"count":143,"type":20},100,"100 Years","OBSERVATIONAL","Bagaev et al. have identified four tumor microenvironment (TME) subtypes that are conserved across diverse cancers and correlated with immunotherapy response in melanoma, bladder, and gastric cancers. They provided a visual tool revealing the TME subtypes integrated with targetable genomic alterations, which provided a planetary view of each tumor that can aid in oncology clinical decision making. We aim to use this tool to prospectively analyse the biopsy specimens of osteosarcomas to identify their TME subtypes so as to deliver appropriate treatment strategy if these osteosarcomas experience disease progression afterwards. We will compare the past sequencing date stored in PKUPH bank so as to compare the event-free survival(EFS) of these patients to check the Superiority of this method later.",[148,149,29,150],"Osteosarcoma","Transcriptome","Precision Medicine",[152,153,154,155],"osteosarcoma","transcriptome","tumor microenviroment","precision medicine","2025-01-21",{"date":158,"type":36},"2025-01-24",{"date":160,"type":20},"2025-03-01",{"date":162,"type":20},"2027-06-01",{"name":164,"class":43},"Peking University People's Hospital",{"id":166,"slug":167,"hasResults":11,"nctId":168,"briefTitle":169,"officialTitle":170,"acronym":4,"eligibilityCriteria":171,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":172,"targetDuration":4,"studyType":145,"phases":4,"briefSummary":174,"conditions":175,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":178,"lastUpdatePostDateStruct":179,"startDateStruct":181,"completionDateStruct":183,"leadSponsor":185,"locationsCount":44},"100530121","the-prognostic-value-of-the-degree-of-pathological-response-of-induction-chemotherapy-for-npc-100530121","NCT06182657","The Prognostic Value of the Degree of Pathological Response of Induction Chemotherapy for NPC","The Prognostic Value of the Degree of Pathological Response at One Cycle of Induction Chemotherapy for Locally Advanced Nasopharyngeal Carcinon-a Prospective Observational Study","Inclusion Criteria:\n\n1. Ability to sign informed consent\n2. Age \\> 18 years at time of study entry\n3. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 (amend based on specific study)\n4. Histological confirmation of NPC (regardless if EBER positive or negative)\n5. Locally advanced NPC, UICC stage III-IVa\n6. Subject is willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations including follow up.\n\nExclusion Criteria:\n\n1. Concurrent enrolment in another clinical study, unless it is an observational (non-interventional) clinical study or during the follow-up period of an interventional study\n2. Distant metastases\n3. Prior systemic anti-cancer therapy (chemotherapy, immunotherapy, endocrine therapy, targeted therapy, radiotherapy, biologic therapy, tumour embolization, monoclonal antibodies) of the locally advanced NPC.\n4. History of another primary malignancy\n5. Female patients who are pregnant\n6. Known allergy or hypersensitivity to any drugs\n7. Judgment by the investigator that the patient is unsuitable to participate in the study and the patient is unlikely to comply with study procedures, restrictions and requirements.",{"count":173,"type":20},300,"This study aims to explore the prognostic value of pathological remission after one cycle of induction chemotherapy in locally advanced nasopharyngeal carcinoma, and the change of immune micro-environment after one cycle induction chemotherapy, including the density of immune cells infiltration and tertiary lymphoid structures.",[176,177,29],"Nasopharyngeal Carcinoma","Pathologic Complete Response","2024-02-07",{"date":180,"type":36},"2024-02-08",{"date":182,"type":36},"2024-01-01",{"date":184,"type":20},"2029-06-30",{"name":186,"class":43},"Jiangxi Provincial Cancer Hospital"]